IP Library › Granted Patent US 9,328,339
Granted Patent B2
US 9,328,339 · App. 14/267,754 · Granted May 3, 2016

Modified factor IX polypeptides and uses thereof

Inventors: Edwin L. Madison (San Francisco, CA); Christopher Thanos (Tiburon, CA); Grant Ellsworth Blouse (Copenhagen S, DK)
Assignee: Catalyst Biosciences, Inc.
C12N9/644C12Y304/21022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,328,339
App. No.
14/267,754
Granted
May 3, 2016
Kind
B2
Abstract

Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Claims (36)

1. A modified FIX polypeptide comprising an amino acid replacement corresponding to T343R or T343K in an unmodified FIX polypeptide, wherein:

corresponding amino acid residues are identified by alignment of the unmodified FIX polypeptide with the polypeptide of SEQ ID NO:3;

the unmodified FIX polypeptide comprises a sequence of amino acids set forth in any of SEQ ID NOS: 2, 3, 20 or 325, or a sequence of amino acid residues having at least 95% sequence identity to the FIX polypeptide sequence set forth in any of SEQ ID NOS: 2, 3, 20 or 325, or is a catalytically active fragment thereof;

the modified FIX polypeptide, when an active form, exhibits one or both of increased catalytic activity and increased procoagulant activity compared with the unmodified FIX polypeptide; and

the modified FIX polypeptide does not contain the amino acid replacements corresponding to F342I/T343R/Y345T.

2. The modified FIX polypeptide of claim 1 , wherein the amino acid replacement corresponds to T343R.

3. The modified FIX polypeptide of claim 1 , further comprising the amino acid replacement R338E or R338D.

4. The modified FIX polypeptide of claim 2 , further comprising the amino acid replacement R338E.

5. The modified FIX polypeptide of claim 1 , comprising an amino acid replacement at residue E410 or at an amino acid residue corresponding to 410 in an unmodified FIX polypeptide, wherein the replacement amino acid is N or S.

6. The modified FIX polypeptide of claim 5 , wherein the amino acid replacement is N.

7. The modified FIX polypeptide of claim 1 , comprising an amino acid replacement at residue E403 or at an amino acid residue corresponding to 403 in an unmodified FIX polypeptide, wherein the replacement amino acid is E.

8. The modified FIX polypeptide of claim 1 , comprising the amino acid replacements R338E/T343R and one or both of R403E and E410N in a mature FIX polypeptide having a sequence set forth in SEQ ID NO:3 or the same replacements at corresponding amino acid residues in an unmodified FIX polypeptide.

9. The modified FIX polypeptide of claim 1 , further comprising the amino acid replacement Y155F.

10. The modified FIX polypeptide of claim 1 , comprising amino acid replacements selected from among R338E/T343R/E410N; Y155F/R338E/T343R/E410N; Y155F/K247N/N249S/T343R/E410N; Y155F/T343R/R403E/E410N; K247N/N249S/T343R/R403E/E410N; Y155F/K247N/N249S/T343R/R403E/E410N; K247N/N249S/R338E/T343R/E410N; Y155F/K247N/N249S/R338E/T343R/E410N; K247N/N249S/R338E/T343R/R403E; Y155F/K247N/N249S/R338E/T343R/R403E; Y155F/K247N/N249S/R338E/T343R; K247N/N249S/R338E/T343R/R403E/E410N; Y155F/K247N/N249S/R338E/T343R/R403E/E410N; Y155F/K247N/N249S/T343R/R403E; Y155F/I251S/R338E/T343R/R403E; Y155F/N260S/R338E/T343R/R403E; Y155F/R338E/T343R/R403E/E410S; R338E/T343R/R403E; Y155F/R338E/T343R/R403E; Y155F/R338E/T343R/R403E/E410N; R338E/T343R/R403E/E410N and R338E/T343R.

11. The modified FIX polypeptide of claim 1 , comprising amino acid replacements selected from among K247N/N249S/R338E/T343R/R403E/E410N, R338E/T343R/E410N and R338E/T343R.

12. The modified FIX polypeptide of claim 9 , further comprising amino acid replacements selected from among Y155F/R338E/T343R/R403E/E410N, Y155F/R338E/T343R/R403E, Y155F/R338E/T343R/R403E/E410S, Y155F/N260S/R338E/T343R/R403E, Y155F/T343R/R403E/E410N and Y155F/R338E/T343R/E410N.

13. A modified FIX polypeptide, comprising the sequence of amino acids set forth in any of SEQ ID NOS: 268, 351, 352, 361-365, 367, 370, 371, 377 and 387-391, or a sequence of amino acids that exhibits at least 95% amino acid sequence identity with the sequence of amino acids set forth in any of SEQ ID NOS: 268, 351, 352, 361-365, 367, 370, 371, 377 and 387-391 or catalytically active fragments thereof that comprise amino acid replacements corresponding to R338E and T343R, wherein:

corresponding replacements are identified by alignment with SEQ ID NO:3; and

the modified FIX polypeptide, when activated, exhibits one or both of increased catalytic activity and increased procoagulant activity compared with the unmodified FIX polypeptide lacking the R338E and T343R replacements.

14. The modified FIX polypeptide of claim 1 , wherein the unmodified FIX polypeptide consists of a sequence of amino acids set forth in any of SEQ ID NOS: 2, 3, 20 or 325.

15. The modified FIX polypeptide of claim 4 , wherein the unmodified FIX polypeptide consists of a sequence of amino acids set forth in any of SEQ ID NOS: 2, 3, 20 or 325.

16. The modified FIX polypeptide of claim 1 that comprises one or more modifications selected from a chemical modification or a post-translational modification, wherein the modified FIX polypeptide is glycosylated, carboxylated, hydroxylated, sulfated, phosphorylated, albuminated, or conjugated to a polyethylene glycol (PEG) moiety.

17. A pharmaceutical composition, comprising the modified FIX polypeptide of claim 1 , in a pharmaceutically acceptable vehicle.

18. The pharmaceutical composition of claim 17 that is formulated for local, systemic, or topical administration.

19. The pharmaceutical composition of claim 17 that is formulated for oral, nasal, pulmonary, buccal, transdermal, subcutaneous, intraduodenal, enteral, parenteral, intravenous, or intramuscular administration.

20. The pharmaceutical composition of claim 17 that is formulated for controlled-release.

21. The pharmaceutical composition of claim 17 that is formulated for single-dosage administration.

22. The modified FIX polypeptide of claim 1 that is glycosylated.

23. The modified FIX polypeptide of claim 1 that is hyperglycosylated.

24. The modified FIX polypeptide of claim 1 that is a mature polypeptide.

25. The modified FIX polypeptide of claim 1 that is a two-chain polypeptide.

26. The modified FIX polypeptide of claim 1 that is a single-chain polypeptide.

27. The modified FIX polypeptide of claim 1 that is activated.

28. The modified FIX polypeptide of claim 1 that is a zymogen.

29. A method, comprising treating a subject by administering the pharmaceutical composition of claim 17 , wherein the subject has a disease or condition that is treated by administration of FIX or a procoagulant.

30. The method of claim 29 , wherein the disease or condition to be treated is selected from among blood coagulation disorders, hematologic disorders, hemorrhagic disorders, hemophilias, and bleeding disorders.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2023
From: CATALYST BIOSCIENCES, INC.
To: GC BIOPHARMA CORP.
Reel/Frame 062943/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2014
From: MADISON, EDWIN L.; THANOS, CHRISTOPHER; BLOUSE, GRANT ELLSWORTH
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 033715/0391 →
Continuity (3)
Continuation 13373118 · Nov 3, 2011
Provisional Application 61456298 · Nov 3, 2010
Related Publication 20140322191A1 · Oct 30, 2014